Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 189

2.

[Costs of chronic obstructive pulmonary disease in patients treated in ambulatory care in Poland].

Jahnz-Różyk K, Targowski T, From S, Faluta T, Borowiec L.

Pneumonol Alergol Pol. 2011;79(5):337-42. Polish.

3.

Economic burden of schizophrenia: empirical analyses from a survey in Thailand.

Phanthunane P, Whiteford H, Vos T, Bertram M.

J Ment Health Policy Econ. 2012 Mar;15(1):25-32.

PMID:
22611090
4.

Resource utilization and cost of heart failure associated with reduced ejection fraction in Swedish patients.

Stålhammar J, Stern L, Linder R, Sherman S, Parikh R, Ariely R, Wikström G.

J Med Econ. 2012;15(5):938-46. doi: 10.3111/13696998.2012.686464. Epub 2012 May 17.

PMID:
22510016
5.

Access to selected diagnostic procedures in the management of heart failure patients in Poland - POLKARD 2005.

Wizner B, Dubiel JS, Opolski G, Fedyk-Łukasik M, Zdrojewski T, Marchel M, Stompór M, Turek P, Czech M, Wyrzykowski B, Mogilnaya I, Jendrzejewski J, Grodzicki T.

Kardiol Pol. 2010 Mar;68(3):265-72.

6.
7.

[Costs of exacerbations of chronic obstructive pulmonary disease in primary and secondary care in 2007--results of multicenter Polish study].

Jahnz-Rózyk K, Targowski T, From S.

Pol Merkur Lekarski. 2009 Mar;26(153):208-14. Polish.

PMID:
19388534
8.

Costs of rheumatoid arthritis in Germany: a micro-costing approach based on healthcare payer's data sources.

Ruof J, Hülsemann JL, Mittendorf T, Handelmann S, von der Schulenburg JM, Zeidler H, Merkesdal S.

Ann Rheum Dis. 2003 Jun;62(6):544-9.

9.

Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).

Reed SD, Friedman JY, Velazquez EJ, Gnanasakthy A, Califf RM, Schulman KA.

Am Heart J. 2004 Jul;148(1):122-8.

PMID:
15215801
10.
11.

Population of Polish patients participating in the Heart Failure Pilot Survey (ESC-HF Pilot).

Sosnowska-Pasiarska B, Bartkowiak R, Wożakowska-Kapłon B, Opolski G, Ponikowski P, Poloński L, Szełemej R, Juszczyk Z, Mirek-Bryniarska E, Drożdż J.

Kardiol Pol. 2013;71(3):234-40. doi: 10.5603/KP.2013.0034.

12.

Economic burden of heart failure in the elderly.

Liao L, Allen LA, Whellan DJ.

Pharmacoeconomics. 2008;26(6):447-62. Review.

PMID:
18489197
13.

Cost-effectiveness of a disease management programme for secondary prevention of coronary heart disease and heart failure in primary care.

Turner DA, Paul S, Stone MA, Juarez-Garcia A, Squire I, Khunti K.

Heart. 2008 Dec;94(12):1601-6. doi: 10.1136/hrt.2007.125708. Epub 2008 May 1.

PMID:
18450843
14.

The burden of preserved ejection fraction heart failure in a real-world Swedish patient population.

Stålhammar J, Stern L, Linder R, Sherman S, Parikh R, Ariely R, Deschaseaux C, Wikström G.

J Med Econ. 2014 Jan;17(1):43-51. doi: 10.3111/13696998.2013.848808. Epub 2013 Oct 25.

PMID:
24066839
15.

Resource utilization and costs following hospitalization of patients with chronic heart failure in the US.

Korves C, Eldar-Lissai A, McHale J, Lafeuille MH, Hwa Ong S, Sheng Duh M.

J Med Econ. 2012;15(5):925-37. doi: 10.3111/13696998.2012.685136. Epub 2012 May 15.

PMID:
22502902
16.

The health care costs of heart failure in Sweden.

Rydén-Bergsten T, Andersson F.

J Intern Med. 1999 Sep;246(3):275-84.

17.

Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. U.S. Carvedilol Heart Failure Study Group.

Fowler MB, Vera-Llonch M, Oster G, Bristow MR, Cohn JN, Colucci WS, Gilbert EM, Lukas MA, Lacey MJ, Richner R, Young ST, Packer M.

J Am Coll Cardiol. 2001 May;37(6):1692-9.

18.

Economic burden of heart failure: investigating outpatient and inpatient costs in Abeokuta, Southwest Nigeria.

Ogah OS, Stewart S, Onwujekwe OE, Falase AO, Adebayo SO, Olunuga T, Sliwa K.

PLoS One. 2014 Nov 21;9(11):e113032. doi: 10.1371/journal.pone.0113032. eCollection 2014.

19.

Treatment pathways, resource use and costs in the management of small cell lung cancer.

Oliver E, Killen J, Kiebert G, Hutton J, Hall R, Higgins B, Bourke S, Paschen B.

Thorax. 2001 Oct;56(10):785-90.

20.

New technologies and potential cost savings related to morbidity and mortality reduction in Class III/IV heart failure patients in Canada.

Bentkover JD, Stewart EJ, Ignaszewski A, Lepage S, Liu P, Cooper J.

Int J Cardiol. 2003 Mar;88(1):33-41.

PMID:
12659982

Supplemental Content

Support Center